about
Platform
from code to cure
An Integrated, AI-Driven Discovery Platform De-Risking the Path to Clinical Success
Request Investment Deck
In Silico Discovery
The Engine Room: Where Data Becomes Insight
Tech-bio capabilities leverage computational power to cut years off initial discovery. Our platform transforms biological complexity into actionable intelligence.
Advanced algorithms mine vast datasets to identify therapeutic opportunities invisible to traditional methods. Speed and precision define our competitive edge.
Core Capabilities
  • Genomic analysis across population-scale datasets
  • Dark Genome interrogation of non-coding regions
  • Multi-omics integration for disease associations
  • Real-time predictive modeling and validation
AI-Powered Target Discovery at Scale
AI-Driven Target ID
Proprietary ML algorithms predict high-value therapeutic targets with superior accuracy. Our models outperform traditional methods by 40%.
Virtual HTS
Screen billions of compounds virtually in days. Dramatically lower material costs while accelerating hit identification timelines.
Structural Biology
High-resolution protein-ligand modeling with quantum-ready algorithms. Predict binding interactions with atomic-level precision.
In Vitro Validation
Translating Theory to Therapeutic Reality
Our in vitro validation processes are designed for precision and speed, ensuring that AI-driven discoveries translate into viable drug candidates ready for preclinical development. We bridge computational insights with rigorous experimental verification.
Seamless Discovery Engine
Our integrated pipeline bridges computational predictions with experimental validation, ensuring a fluid transition from in silico insights to wet lab verification.
SAR & Optimization
Advanced Structure-Activity Relationship (SAR) analysis and iterative optimization strategies rapidly refine molecular structures, enhancing potency and selectivity.
Rigorous Validation
Our robust experimental validation framework employs a suite of biochemical and cellular assays, confirming target engagement and functional efficacy with high precision.
Data Rigor & Reproducibility
Commitment to stringent data rigor and reproducibility protocols underpins every experiment, ensuring reliable and verifiable results through standardized methodologies.
In Vitro Validation
Proof-of-the-Concept
Robust validation in biological systems prevents costly late-stage failures. Early confirmation of target biology de-risks the entire pipeline.
CRISPR Gene Editing
Precision knockout studies confirm target modulation reverses disease phenotypes in relevant cell lines.
Custom Assays
Bespoke biochemical assays with high sensitivity. Fluorescence, luminescence, and FRET technologies ensure reproducibility.
Patient Models
iPSCs and organoids provide human-relevant tissue testing. A clinical trial in a dish approach.
Biomarker Discovery
Early identification of predictive biomarkers enables patient stratification for regulatory success.
From Molecules to Medicines: The Refinement
We improve potency while simultaneously solving safety and delivery challenges. Every iteration advances multiple parameters.
01
Medicinal Chemistry
Iterative synthesis improves potency, selectivity, and strengthens IP position.
02
Structure-Based Design
X-ray and Cryo-EM data guide modifications with atomic precision.
03
ADME Profiling
Rapid assessment discards undruggable compounds early in the funnel.
04
Liability De-risking
Early screens for cardiac safety and mutagenicity ensure clean candidates.
Preclinical Development
The Gatekeeper: Safety & Efficacy
GLP-compliant studies demonstrate translatability to humans. This stage determines IND readiness and investor confidence.
1
Disease Pharmacology Models
Validated rodent and non-rodent models mimic human pathology. Xenograft and metabolic disease models demonstrate in vivo efficacy.
2
PK/PD Analysis
Detailed tracking of drug exposure in blood and tissues. Biological effects correlated with concentration over time.
3
GLP Toxicology
Regulatory-compliant safety studies required for IND applications. Dose-range finding and repeat-dose toxicity testing.
4
Safety Pharmacology
Specialized testing ensures no adverse immune responses. Vital organ function monitoring across respiratory, cardiovascular, and CNS systems.
Why Invest? Our Competitive Moat
Integrated Feedback Loops
Wet-lab data instantly feeds back into bioinformatics models. Our AI becomes smarter with every experiment, compounding learning efficiency.
Accelerated Timelines
We reduce industry standard Target-to-IND timelines by 45%. Traditional approaches take 4-6 years; we deliver faster with higher confidence.
Diverse Modalities
Platform capabilities span small molecules, biologics, and peptides. Flexibility to pursue optimal modality for each target maximizes success probability.
Ready to Transform Drug Discovery Together?
Partner With Us
Our platform de-risks the path from target to clinic. We combine computational power with biological validation to accelerate therapeutic development.
Join leading investors backing the future of AI-driven drug discovery. Let's discuss how our technology can advance your portfolio.
Proprietary platform integrating bioinformatics, target validation, lead optimization, and GLP-compliant preclinical development. Accelerating the journey from code to cure.